- Report
- March 2026
- 200 Pages
Global
From €2490EUR$2,789USD£2,131GBP
- Report
- April 2026
Global
From €4374EUR$4,900USD£3,744GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1116EUR$1,250USD£955GBP
- Report
- December 2024
- 68 Pages
Global
From €3526EUR$3,950USD£3,018GBP
- Report
- June 2024
- 200 Pages
Global
From €7097EUR$7,950USD£6,074GBP
- Report
- May 2024
- 134 Pages
Global
From €2677EUR$2,999USD£2,291GBP
€3570EUR$3,999USD£3,055GBP
The Polymyositis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Polymyositis is an inflammatory disorder that affects the muscles, causing muscle weakness and pain. Treatment for this condition typically involves a combination of medications, physical therapy, and lifestyle changes. Common medications used to treat polymyositis include corticosteroids, immunosuppressants, and biologics.
The Polymyositis Drug market is highly competitive, with a number of companies offering products for the treatment of this condition. Companies in this market include AbbVie, Amgen, Biogen, Celgene, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. These companies are engaged in research and development of new drugs and therapies for the treatment of polymyositis. Show Less Read more